Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 561 - 580 results of 100,277 for search '(( 5 ((step decrease) OR (mean decrease)) ) OR ( 5 ((a decrease) OR (nn decrease)) ))', query time: 0.90s Refine Results
  1. 561
    Resveratrol decreases activated-STAT1 levels in the nucleus of cytokine-stimulated HT-29 cells more efficiently than 5-ASA.

    Resveratrol decreases activated-STAT1 levels in the nucleus of cytokine-stimulated HT-29 cells more efficiently than 5-ASA. by Diana Serra (455187)

    Published 2014
    Save to List
    Saved in:
  2. 562
    Focal adhesion kinase phosphorylation levels within the optic nerve head decrease steadily after intraocular pressure elevation.

    Focal adhesion kinase phosphorylation levels within the optic nerve head decrease steadily after intraocular pressure elevation. by Shandiz Tehrani (3365900)

    Published 2016
    Save to List
    Saved in:
  3. 563
    Cell adhesion was decreased by simvastatin and benznidazole during <i>Trypanosoma cruzi</i> infection.

    Cell adhesion was decreased by simvastatin and benznidazole during <i>Trypanosoma cruzi</i> infection. by Carolina Campos-Estrada (403914)

    Published 2015
    Save to List
    Saved in:
  4. 564
    Intranasal administration of perindopril decreases amyloid plaques and CD11b staining in the cortex of 3-month old 5XFAD mice.

    Intranasal administration of perindopril decreases amyloid plaques and CD11b staining in the cortex of 3-month old 5XFAD mice. by Nofar Torika (3169497)

    Published 2016
    Save to List
    Saved in:
  5. 565
    Intranasal administration of telmisartan decreases amyloid plaques and CD11b staining in the cortex of 3-month-old 5XFAD mice.

    Intranasal administration of telmisartan decreases amyloid plaques and CD11b staining in the cortex of 3-month-old 5XFAD mice. by Nofar Torika (3169497)

    Published 2016
    Save to List
    Saved in:
  6. 566
    The Activation Effects of Low Level Isopropyl Alcohol Exposure on Arterial Blood Pressures Are Associated with Decreased 5-Hydroxyindole Acetic Acid in Urine

    The Activation Effects of Low Level Isopropyl Alcohol Exposure on Arterial Blood Pressures Are Associated with Decreased 5-Hydroxyindole Acetic Acid in Urine by Zhiqiang Zhao (201543)

    Published 2016
    Save to List
    Saved in:
  7. 567
    Sign-tracking (ST)–Goal-tracking (GT) score for day 5.

    Sign-tracking (ST)–Goal-tracking (GT) score for day 5. by Silvia Fuentes (4759686)

    Published 2018
    Save to List
    Saved in:
  8. 568
    Hepatic irradiation decreases the proportion of DX5<sup>–</sup>TRAIL<sup>+</sup> lrNK cells for up to two months.

    Hepatic irradiation decreases the proportion of DX5<sup>–</sup>TRAIL<sup>+</sup> lrNK cells for up to two months. by Ryosuke Nakano (4557097)

    Published 2018
    “…NK cells were divided into DX5<sup>–</sup>TRAIL<sup>+</sup> lrNK cells and DX5<sup>+</sup>TRAIL<sup>−</sup> cNK cells. …”
    Save to List
    Saved in:
  9. 569
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 570
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 571
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 572
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 573
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 574
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 575
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 576
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 577
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 578
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 579
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 580
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: